LOTAM: A RANDOMIZED, PHASE III CLINICAL TRIAL OF LOW-DOSE TAMOXIFEN FOR SELECTED PATIENTS WITH MOLECULAR LOW-RISK EARLY-STAGE BREAST CANCER

Sponsor:

Alliance for Clinical Trials in Oncology

Sponsor Study ID:

A012301

CTO #:

104192

NCT Number:

NCT06671912

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Breast

Study Objectives:

To evaluate whether the recurrence-free interval (RFI) with low-dose tamoxifen is non-inferior to standard-of-care endocrine therapy among post-menopausal women with early-stage, low molecular risk breast cancer.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)